The Priority Review

Tag

FDA

70 stories ยท page 2 of 6

Stories

  1. Regulation

    FDA classifies wearable vibration device for orthopedic use as class II

    The FDA finalized an order classifying the wearable vibration device for orthopedic use into class II with special controls, stating the classification will provide a reasonable assurance of the safety and effectiveness of the device. The agency said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

  2. Regulation

    FDA classifies mild cognitive impairment prognostic software as class II

    The FDA issued a final order classifying the prognostic assessment software of mild cognitive impairment into class II with special controls, as stated in the Federal Register. The order notes that this classification should provide reasonable assurance of safety and effectiveness and may enhance patient access by reducing regulatory burdens.

  3. Regulation

    FDA releases final guidance on reducing transfusion-transmitted Hepatitis B virus

    FDA announces availability of the final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus" on November 3, 2026. The guidance supersedes several earlier documents and applies to the collection of Whole Blood and blood components, including Source Plasma.

  4. Regulation

    FDA releases final guidance on potency assurance for cellular and gene therapy products

    The notice, published November 3, 2026, announces the availability of the guidance with docket number FDA-2023-D-4299. It recommends a comprehensive strategy grounded in quality risk management for both investigational and licensed CGT products.

  5. Regulation

    FDA actions, week of November 2, 2026: 3 approvals, 3 rules, 1 proposed rule, 2 notices, 1 announcement

    The FDA published 10 actions in the week of November 2 to 8, 2026: 3 approval announcements, 3 final rules in the Federal Register, 1 proposed rule in the Federal Register, 2 notices in the Federal Register and 1 press announcement.

  6. Regulation

    Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3

    Roche announced the FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3 (RP3), a flexible syndromic test that detects up to 19 viral and bacterial targets from a single nasopharyngeal swab. The panel offers up to five customizable configurations, requires less than one minute of hands-on time, and delivers results in under two hours.

  7. Regulation

    FDA issues final guidance for cell and gene therapy manufacturers

    The FDA today issued final guidance for cellular and gene therapy (CGT) manufacturers, replacing its 2011 potency testing guidance and recommending a Potency Assurance Strategy for products treating serious or life-threatening conditions. The FDA will host a webinar on December 10, 2026 to help stakeholders understand and implement the guidance.

  8. Regulation

    FDA proposes changes to infant formula nutrient specifications and labeling

    The FDA proposes to amend the minimum and/or maximum levels of iodine, vitamin A, vitamin D, and manganese, change the unit of measure for vitamin A from IU to microgram Retinol Activity Equivalents and for vitamin D from IU to micrograms, and modify labeling requirements. Comments on the rule are due by March 2, 2027.

  9. Approvals

    FDA approves first plasmid DNA-based immunotherapy for adults with RRP

    The FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV. In an open-label multicenter trial of 32 adults, 27% of patients who had at least three baseline surgeries did not require any surgery during the first year after treatment.

  10. Regulation

    FDA releases revised draft guidance on drug delivery device performance

    The FDA announced the availability of a revised draft guidance published October 30, 2026. The guidance replaces the draft guidance announced July 1, 2024 and provides recommendations for development and organization of device drug-delivery performance information.

  11. Regulation

    FDA classifies radiology software for fibrotic lung disease as class II

    The FDA finalized an order classifying the radiology software for referral of findings related to fibrotic lung disease as class II with special controls that will be part of the codified language for classification. The agency said the classification provides reasonable assurance of safety and effectiveness and may enhance patients' access to beneficial innovative devices by reducing regulatory burdens.

  12. Regulation

    FDA issues priority review voucher for EMCITATE (tiratricol)

    The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).